Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept.
Level 2 - randomized trial
Individual randomized, double-blind, placebo-controlled trial
PubMed 22162828 · doi:10.1038/tp.2011.22
What was done
Outpatients with major depressive disorder were randomized in a double-blind, 4-week trial to sertraline (up to 150 mg/day; n=43) or placebo (n=46). Baseline serum samples were profiled using a liquid chromatography electrochemical array platform to generate digital metabolic profiles. Clinical response was defined as a ≥50% reduction from baseline to week 4 on the 17-item Hamilton Rating Scale for Depression total score. Multivariate predictive models were generated and evaluated using leave-one-out cross-validation.
What was found
Baseline metabolic profiles partially separated responders from non-responders in both treatment arms. The overall correct classification rate was 81% for sertraline models and 72% for placebo models. Pathways implicated in distinguishing responders from non-responders for both sertraline and placebo included phenylalanine, tryptophan, purine, and tocopherol. Dihydroxyphenylacetic acid, tocopherols, and serotonin were common distinguishing metabolites for both arms.
Why it matters
This proof-of-concept study demonstrates that peripheral metabolomic signatures might predict early antidepressant response versus placebo, offering a potential path toward stratified treatment in major depression.
Limits
The sample size was small (89 total participants). Predictive models were validated solely using leave-one-out internal cross-validation without an external validation cohort. The trial duration was short (4 weeks), and specific effect sizes or confidence intervals for individual metabolite predictors were not reported in the abstract.
Cited by
- supports SSRIs improve major depressive disorder by approximately 50% in randomized controlled trials.